Free Trial

PTC Therapeutics (PTCT) News Today

PTC Therapeutics logo
$47.86 +1.93 (+4.20%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$46.36 -1.50 (-3.13%)
As of 05:49 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

PTCT Latest News

PTC Therapeutics, Inc. stock logo
Toronto Dominion Bank Invests $148.36 Million in PTC Therapeutics, Inc. (NASDAQ:PTCT)
Toronto Dominion Bank purchased a new position in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 3,286,729 shares of the biopharmaceutical company's stock, valued
PTC Therapeutics, Inc. stock logo
Two Sigma Investments LP Has $7.83 Million Holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT)
Two Sigma Investments LP decreased its position in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 45.4% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 173,352 shares of the biopharmaceutical company's stock
PTC Therapeutics, Inc. stock logo
Quantinno Capital Management LP Makes New $436,000 Investment in PTC Therapeutics, Inc. (NASDAQ:PTCT)
Quantinno Capital Management LP acquired a new position in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) during the fourth quarter, according to the company in its most recent filing with the SEC. The fund acquired 9,656 shares of the biopharmaceutical company's stock, valued at approximately
PTC Therapeutics, Inc. stock logo
Woodline Partners LP Buys New Position in PTC Therapeutics, Inc. (NASDAQ:PTCT)
Woodline Partners LP purchased a new position in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 155,883 shares of the biopharmaceutical company's stock, va
PTC Therapeutics, Inc. stock logo
State of Wyoming Makes New Investment in PTC Therapeutics, Inc. (NASDAQ:PTCT)
State of Wyoming purchased a new position in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 5,776 shares of the biopharmaceutical company's stock,
PTC Therapeutics, Inc. stock logo
BNP Paribas Financial Markets Has $465,000 Holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT)
BNP Paribas Financial Markets reduced its holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 85.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,292 shares of the biopharmaceutical c
PTC Therapeutics, Inc. stock logo
ProShare Advisors LLC Buys 6,164 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT)
ProShare Advisors LLC raised its stake in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 32.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 25,102 shares of t
PTC Therapeutics, Inc. stock logo
Millennium Management LLC Purchases 89,959 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT)
Millennium Management LLC boosted its position in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 41.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 309,423 shares of the biopharmaceutical c
PTC Therapeutics, Inc. stock logo
Bank of America Corp DE Sells 58,187 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT)
Bank of America Corp DE reduced its holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 18.5% during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 256,536 shares of the biopharmaceutical company's stock after
PTC Therapeutics, Inc. stock logo
Voloridge Investment Management LLC Sells 92,168 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT)
Voloridge Investment Management LLC decreased its holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 14.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 568,364 shares of the biopharmace
PTC Therapeutics, Inc. stock logo
Two Sigma Advisers LP Reduces Stock Holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT)
Two Sigma Advisers LP trimmed its position in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 16.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 360,442 shares of the biopharmaceutical com
PTC Therapeutics, Inc. stock logo
PTC Therapeutics, Inc. (NASDAQ:PTCT) Stock Position Raised by Nuveen Asset Management LLC
Nuveen Asset Management LLC lifted its holdings in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 34.0% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 1,077,794 shares of the biopharmaceutical
PTC Therapeutics, Inc. stock logo
Deutsche Bank AG Boosts Stake in PTC Therapeutics, Inc. (NASDAQ:PTCT)
Deutsche Bank AG boosted its stake in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 92.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 94,378 shares of the biopharmaceutical company
PTC Therapeutics, Inc. stock logo
Rafferty Asset Management LLC Sells 23,231 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT)
Rafferty Asset Management LLC trimmed its stake in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 22.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 78,032 shares of the biopharmaceutical compa
PTC Therapeutics, Inc. stock logo
Lazard Asset Management LLC Acquires 34,069 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT)
Lazard Asset Management LLC lifted its holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 294.3% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 45,647 shares of the biopharmaceutical comp
PTC Therapeutics, Inc. stock logo
PTC Therapeutics, Inc. (NASDAQ:PTCT) Holdings Boosted by Point72 Asset Management L.P.
Point72 Asset Management L.P. boosted its position in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 150.6% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 1,443,362 shares of the biopharmaceutical company's
PTC Therapeutics, Inc. stock logo
Point72 Hong Kong Ltd Purchases 21,034 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT)
Point72 Hong Kong Ltd boosted its position in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 184.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 32,436 shares of the biopharmaceutical company's st
PTC Therapeutics, Inc. stock logo
PTC Therapeutics (NASDAQ:PTCT) Rating Lowered to Buy at StockNews.com
StockNews.com downgraded shares of PTC Therapeutics from a "strong-buy" rating to a "buy" rating in a report on Friday.
PTC Therapeutics, Inc. stock logo
14,998 Shares in PTC Therapeutics, Inc. (NASDAQ:PTCT) Acquired by Graham Capital Management L.P.
Graham Capital Management L.P. bought a new position in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 14,998 shares of the biopharmaceutical company's stock,
PTC Therapeutics, Inc. stock logo
MPM Bioimpact LLC Has $19.63 Million Stock Holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT)
MPM Bioimpact LLC raised its stake in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 384.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 434,767 shares of the biopharmaceutical com
PTC Therapeutics, Inc. stock logo
Parkman Healthcare Partners LLC Has $8.01 Million Stock Holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT)
Parkman Healthcare Partners LLC reduced its stake in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 9.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 177,368 shares of the biopharmaceutical
PTC Therapeutics, Inc. stock logo
PTC Therapeutics, Inc. (NASDAQ:PTCT) Position Lifted by OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC
OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 49.2% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 46,894 shares of the biopharmaceutical
PTC Therapeutics, Inc. stock logo
Janus Henderson Group PLC Has $105.02 Million Position in PTC Therapeutics, Inc. (NASDAQ:PTCT)
Janus Henderson Group PLC boosted its position in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 24.4% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 2,325,915 shares of the biopharmaceutical company's stock after purchasi
PTC Therapeutics, Inc. stock logo
Dimensional Fund Advisors LP Takes $4.74 Million Position in PTC Therapeutics, Inc. (NASDAQ:PTCT)
Dimensional Fund Advisors LP bought a new stake in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 105,050 shares of the biopharmaceutical company's stock
PTC Therapeutics, Inc. stock logo
Jacobs Levy Equity Management Inc. Sells 659,778 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT)
Jacobs Levy Equity Management Inc. trimmed its position in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 44.4% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 826,519 shares of the biopharmaceutical company's stock
PTC Therapeutics, Inc. stock logo
Northern Trust Corp Grows Position in PTC Therapeutics, Inc. (NASDAQ:PTCT)
Northern Trust Corp lifted its holdings in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 7.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 727,976 shares of the biopharmaceutical
PTC Therapeutics, Inc. stock logo
Brevan Howard Capital Management LP Takes $551,000 Position in PTC Therapeutics, Inc. (NASDAQ:PTCT)
Brevan Howard Capital Management LP purchased a new position in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 12,197 shares of the biopharmaceutical co
PTC Therapeutics, Inc. stock logo
PTC Therapeutics (NASDAQ:PTCT) Rating Increased to Buy at Bank of America
Bank of America upgraded PTC Therapeutics from a "neutral" rating to a "buy" rating and set a $68.00 target price for the company in a report on Friday.
PTC Therapeutics, Inc. stock logo
Leerink Partnrs Has Bullish Forecast for PTCT Q1 Earnings
PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) - Investment analysts at Leerink Partnrs lifted their Q1 2025 earnings estimates for PTC Therapeutics in a report issued on Tuesday, May 6th. Leerink Partnrs analyst J. Schwartz now forecasts that the biopharmaceutical company will post earnings
PTC Therapeutics, Inc. stock logo
William Blair Lifts Earnings Estimates for PTC Therapeutics
PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) - Equities researchers at William Blair increased their Q1 2025 earnings per share estimates for shares of PTC Therapeutics in a report released on Wednesday, May 7th. William Blair analyst S. Corwin now expects that the biopharmaceutical company
PTC Therapeutics, Inc. stock logo
PTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Purchased by Cubist Systematic Strategies LLC
Cubist Systematic Strategies LLC raised its stake in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 133.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 141,410 shares of the biopharmace
PTC Therapeutics, Inc. stock logo
Driehaus Capital Management LLC Makes New $46.99 Million Investment in PTC Therapeutics, Inc. (NASDAQ:PTCT)
Driehaus Capital Management LLC bought a new stake in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 1,041,059 shares of the biopharmaceutical co
PTC Therapeutics, Inc. stock logo
AQR Capital Management LLC Sells 32,230 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT)
AQR Capital Management LLC cut its holdings in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 17.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 157,349 shares of the bi
PTC Therapeutics, Inc. stock logo
PTC Therapeutics (NASDAQ:PTCT) Shares Gap Up Following Strong Earnings
PTC Therapeutics (NASDAQ:PTCT) Shares Gap Up on Strong Earnings
PTC Therapeutics, Inc. stock logo
Cantor Fitzgerald Cuts PTC Therapeutics (NASDAQ:PTCT) Price Target to $112.00
Cantor Fitzgerald cut their target price on shares of PTC Therapeutics from $113.00 to $112.00 and set an "overweight" rating for the company in a research report on Wednesday.
PTC Therapeutics, Inc. stock logo
JPMorgan Chase & Co. Lowers PTC Therapeutics (NASDAQ:PTCT) Price Target to $67.00
JPMorgan Chase & Co. dropped their price objective on PTC Therapeutics from $75.00 to $67.00 and set an "overweight" rating on the stock in a research note on Wednesday.
PTC Therapeutics, Inc. stock logo
PTC Therapeutics (NASDAQ:PTCT) Upgraded to Neutral at Citigroup
Citigroup raised shares of PTC Therapeutics from a "sell" rating to a "neutral" rating and lowered their target price for the stock from $50.00 to $40.00 in a research note on Wednesday.
PTC Therapeutics, Inc. stock logo
Blackstone Inc. Has $47.83 Million Position in PTC Therapeutics, Inc. (NASDAQ:PTCT)
Blackstone Inc. trimmed its holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 3.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,059,574 shares of the biopharmaceutical company's stock after sel
Get PTC Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for PTCT and its competitors with MarketBeat's FREE daily newsletter.

PTCT Media Mentions By Week

PTCT Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

PTCT
News Sentiment

1.19

1.03

Average
Medical
News Sentiment

PTCT News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

PTCT Articles
This Week

17

8

PTCT Articles
Average Week

Get PTC Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for PTCT and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:PTCT) was last updated on 5/28/2025 by MarketBeat.com Staff
From Our Partners